Vemurafenib and Obinutuzumab as Frontline Therapy for Hairy Cell Leukemia-Reference-Cited by-同舟云学术

Vemurafenib and Obinutuzumab as Frontline Therapy for Hairy Cell Leukemia

Published:2023-09-26 Issue:10 Volume:2 Page:
ISSN:2766-5526
Container-title:NEJM Evidence
language:en
Short-container-title:NEJM Evidence

Author:

Park Jae H.¹²,Devlin Sean³,Durham Benjamin H.⁴,Winer Eric S.⁵,Huntington Scott⁶,von Keudell Gottfried⁶⁷,Vemuri Shreya⁸,Shukla Madhulika⁸,Falco Victoria⁸,Cuello Bernadette¹,Gore Steven⁶⁹,Stone Richard⁵,Abdel-Wahab Omar¹¹⁰,Tallman Martin S.¹¹¹¹²

Affiliation:

1. Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York

2. Department of Medicine, Weill Cornell Medicine, New York

3. Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York

4. Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York

5. Leukemia Service, Department of Medicine, Dana-Farber Cancer Institute, Boston

6. Yale Cancer Center, New Haven, CT

7. Beth Israel Deaconess Cancer Center, Boston

8. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York

9. National Cancer Institute, Bethesda, MD

10. Molecular Pharmacology Program, Sloan Kettering Institute, New York

11. Department of Medicine, Northwestern Comprehensive Cancer Center, Chicago

12. Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago

Publisher

Massachusetts Medical Society

Reference28 articles.

1. BRAFMutations in Hairy-Cell Leukemia

2. Hematopoietic Stem Cell Origin of BRAF V600E Mutations in Hairy Cell Leukemia

3. Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation

4. Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia

5. Hairy cell leukemia: short review, today’s recommendations and outlook

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New Targeted Therapy Combination Holds Promise to Untangle Hairy Cell Leukemia;NEJM Evidence;2023-09-26